Abstract | BACKGROUND: MATERIALS AND METHODS: Overall, 610 patients were enrolled in CS21, wherein PSA and FSH levels were evaluated monthly. CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix. PSA and FSH levels were evaluated in CS21A for 3 months after cross-over. The associations between measurements were assessed using Spearman's correlation coefficient. The impact of class variables on FSH suppression were evaluated using Analysis of Variance. RESULTS: Rapid PSA and FSH suppression was observed and maintained in the degarelix arm (CS21 and CS21A), while patients on leuprolide experienced rising PSA during CS21. Patients crossed-over from leuprolide to degarelix achieved a suppression of FSH and a significant PSA decrease. PSA and FSH levels were significantly (p < .05) correlated at months 1, 3, 6, 12 and 13 in the degarelix arm. CONCLUSIONS: Significant FSH suppression with GnRH antagonists may explain its advantage over GnRH agonists in terms of better prostate cancer control. The effect of profound FSH suppression is analogous to the need for profound testosterone suppression for tumor control.
|
Authors | E David Crawford, B Tombal, T Keane, F Boccardo, K Miller, N Shore, J W Moul, J-E Damber, L Collette, B-E Persson |
Journal | Scandinavian journal of urology
(Scand J Urol)
2018 Oct - Dec
Vol. 52
Issue 5-6
Pg. 349-357
ISSN: 2168-1813 [Electronic] Sweden |
PMID | 30624128
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Oligopeptides
- acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
- Gonadotropin-Releasing Hormone
- Follicle Stimulating Hormone
- KLK3 protein, human
- Kallikreins
- Prostate-Specific Antigen
- Leuprolide
|
Topics |
- Aged
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Drug Substitution
- Follicle Stimulating Hormone
(metabolism)
- Gonadotropin-Releasing Hormone
(agonists, antagonists & inhibitors)
- Humans
- Kallikreins
(metabolism)
- Leuprolide
(therapeutic use)
- Male
- Middle Aged
- Oligopeptides
(therapeutic use)
- Prostate-Specific Antigen
(metabolism)
- Prostatic Neoplasms
(drug therapy, metabolism)
|